The tyrosine phosphatase Shp-2 mediates intracellular signaling initiated by Ret mutants.

Authors: D'Alessio, A  Califano, D  Incoronato, M  Santelli, G  Florio, T  Schettini, G  Carlomagno, M S  Cerchia, L  de Franciscis, V 
Citation: D'Alessio A, etal., Endocrinology. 2003 Oct;144(10):4298-305. Epub 2003 Jun 19.
Pubmed: (View Article at PubMed) PMID:12959980
DOI: Full-text: DOI:10.1210/en.2003-0620

The Src homology 2-containing tyrosine phosphatase, Shp-2, is a crucial enzyme that mediates intracellular signaling and is implicated in cell proliferation and differentiation. Here we investigated the involvement of the Shp-2 tyrosine phosphatase in determining the downstream signaling pathways initiated by the Ret oncogene, carrying either the cysteine 634 to tyrosine or the methionine 918 to threonine substitutions. These mutations convert the receptor tyrosine kinase, Ret, into a dominant transforming protein and induce constitutive activation of its intrinsic tyrosine kinase activity leading to congenital and sporadic cancers in neuroendocrine organs. Using the PC12, rat pheochromocytoma cell line, as model system, we show that Shp-2 mediates immediate-early gene expression if induced by either of the mutant alleles. Furthermore, we show that Shp-2 activity is required for RetM918T-induced Akt activation. The results indicate that Shp-2 is a downstream mediator of the mutated receptors RetC634Y and RetM918T, thus suggesting that it may act as a limiting factor in Ret-associated endocrine tumors, in the neoplastic syndromes multiple endocrine neoplasia types 2A and 2B.

Annotation

Gene Ontology Annotations
Objects Annotated

Additional Information

 
CRRD Object Information
CRRD ID: 12743580
Created: 2017-02-08
Species: All species
Last Modified: 2017-02-08
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.